Checkpoint immunotherapy utilizing PD-1 blockade has become the standard of care for metastatic melanoma. While this treatment is effective in 40% of patients, the other 60% develop resistance, leading to tumor regrowth. A multidisciplinary research team led by the University of California, Irvine has identified a new strategy that could enhance the therapeutic effectiveness of this therapy by targeting the communication between immune cells within the tumor.
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Allen Institute For Cell Science Announces Leadership Changes
December 11, 2020 GMT
SEATTLE, Wash., Dec. 11, 2020 /PRNewswire/ The Allen Institute for Cell Science, a division of the Allen Institute, announced today that Ruwanthi (Ru) Gunawardane, Ph.D., has been named Executive Director, effective January 9, 2021, providing executive direction and leadership. Susanne Rafelski, Ph.D., Deputy Director, will manage and lead the scientific research. Rick Horwitz, Ph.D., will assume the role of the Institute’s Senior Advisor and Inaugural Executive Director, Emeritus, and will be active in the Institute’s dissemination and alliance efforts.